Parkinson disease expert Daniel Kremens, MD, JD, offers commentary on various presentations of novel therapies from the 2024 American Academy of Neurology Annual Meeting.
EP. 1: Optimizing Dosing and Treatment Selection of Amantadine
Daniel Kremens, MD, JD, provided commentary on a number of various amantadine formulations for Parkinson disease, and how timing of dosing impacts efficacy.
EP. 2: Use of Antiemetics in Parkinson Care
In this conversation, Kremens discussed the common use of antiemetics in Parkinson disease, the real-world data surrounding these agents, and whether there are certain clinical advantages to apomorphine hydrochloride injection.
EP. 3: Emerging Novel Therapies in Development for PD
Kremens gave thoughts on the use of several investigational continuous agents, including IPX203, risvodetinib, and P2B001.
EP. 4: Investigational Pump Agents to Treat Parkinson Disease
In this segment, Kremens described pump therapies currently in development, such as ND0612 and ABBV-951.